Follicular lymphoma · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #06 | — | R 190 790 | 21d | — | — | ~7 | ~R 476 974 indirect | — |
Lenalidomide and Rituximab (R2) Variant #08 | — | R 185 508 | 28d | ~26.7 mo | — | ~5 | ~R 297 838 PFS proxy · indirect | 4 |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
Rituximab and hyaluronidase monotherapy Variant #01 Partial | — | R 25 905 | 28d | — | — | ~1 | ~R 25 905 PFS proxy · indirect | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | 126.0 mo | — | 1 | — | 2 |
Placebo Partial | — | — | — | — | — | — | — | 1 |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | ~5.4 mo | ~17.5 mo | ~2 | — | 10 |
7 of 7 regimens shown